S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Avant Diagnostics Stock Forecast, Price & News

+0.44 (+2.03%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
772,880 shs
Average Volume
1.35 million shs
Market Capitalization
$4.33 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AVDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Avant Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Avant Diagnostics logo

About Avant Diagnostics

Avant Diagnostics, Inc., a commercial-stage molecular data-generating company, focuses on the development and commercialization of proprietary data-generating assays that provide information for physicians and patients in the areas of cancers. It owns license and distribution right for OvaDx, a noninvasive proteomics diagnostic screening test for the early detection of ovarian cancer. The company was founded in 2009 and is based in Washington, District of Columbia.


Avant Diagnostics Sees Unusually Large Options Volume (OTCMKTS:AVDX)
November 17, 2021 |  americanbankingnews.com
AvidXchange Announces Third Quarter 2021 Financial Results
November 16, 2021 |  finance.yahoo.com
AvidXchange Announces Early IPO Lock-up Release
November 16, 2021 |  finance.yahoo.com
Avant Diagnostics (OTCMKTS:AVDX) Now Covered by Wolfe Research
November 8, 2021 |  americanbankingnews.com
Barclays Begins Coverage on Avant Diagnostics (OTCMKTS:AVDX)
November 8, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Prepackaged software
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$185.93 million


Pretax Margin




Free Float
Market Cap
$4.33 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End


Overall MarketRank

1.72 out of 5 stars

Analyst Opinion: 4.4Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Avant Diagnostics (OTCMKTS:AVDX) Frequently Asked Questions

Is Avant Diagnostics a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avant Diagnostics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Avant Diagnostics stock.
View analyst ratings for Avant Diagnostics
or view top-rated stocks.

How has Avant Diagnostics' stock price been impacted by COVID-19?

Avant Diagnostics' stock was trading at $0.0320 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AVDX stock has increased by 68,931.3% and is now trading at $22.09.
View which stocks have been most impacted by COVID-19

How were Avant Diagnostics' earnings last quarter?

Avant Diagnostics Inc (OTCMKTS:AVDX) posted its quarterly earnings data on Tuesday, November, 16th. The company reported ($0.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.57. The firm earned $65.18 million during the quarter, compared to analysts' expectations of $61.55 million. The company's quarterly revenue was up 36.9% compared to the same quarter last year.
View Avant Diagnostics' earnings history

What guidance has Avant Diagnostics issued on next quarter's earnings?

Avant Diagnostics updated its FY 2021 earnings guidance on Tuesday, November, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $244.50 million-$245.50 million.

What price target have analysts set for AVDX?

9 Wall Street analysts have issued 12 month price targets for Avant Diagnostics' shares. Their forecasts range from $28.00 to $31.00. On average, they expect Avant Diagnostics' share price to reach $29.00 in the next year. This suggests a possible upside of 31.3% from the stock's current price.
View analysts' price targets for Avant Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are Avant Diagnostics' key executives?

Avant Diagnostics' management team includes the following people:
  • Mr. Jeffrey M. Busch, Exec. Chairman (Age 59)
  • Dr. Michael I. Ruxin, Pres, CEO & Director (Age 73)
  • Mr. Scott VanderMeer, Interim Chief Financial Officer (Age 32)
  • Dr. Glenn D. Hoke Ph.D., Chief Scientific Officer
  • Ms. Rene A. Schena, Chairman & CEO of Arrayit Corp. (Age 56)

What other stocks do shareholders of Avant Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avant Diagnostics investors own include Bottomline Technologies (de) (EPAY), Sysco (SYY), American Airlines Group (AAL), AnaptysBio (ANAB), Aptevo Therapeutics (APVO), American Railcar Industries (ARII), Boeing (BA), Biogen (BIIB), BankUnited (BKU) and Cray (CRAY).

What is Avant Diagnostics' stock symbol?

Avant Diagnostics trades on the OTCMKTS under the ticker symbol "AVDX."

When did Avant Diagnostics' quiet period expire?

Avant Diagnostics' quiet period expired on Monday, November 22nd. Avant Diagnostics had issued 26,400,000 shares in its initial public offering on October 13th. The total size of the offering was $660,000,000 based on an initial share price of $25.00. During Avant Diagnostics' quiet period, insiders and any underwriters that worked on the IPO were prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Avant Diagnostics?

Shares of AVDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avant Diagnostics' stock price today?

One share of AVDX stock can currently be purchased for approximately $22.09.

How much money does Avant Diagnostics make?

Avant Diagnostics has a market capitalization of $4.33 billion and generates $185.93 million in revenue each year.

How many employees does Avant Diagnostics have?

Avant Diagnostics employs 2,021 workers across the globe.

What is Avant Diagnostics' official website?

The official website for Avant Diagnostics is avantdiagnostics.com.

Where are Avant Diagnostics' headquarters?

Avant Diagnostics is headquartered at 1050 30TH STREET NW SUITE 107, WASHINGTON DC, 20007.

How can I contact Avant Diagnostics?

Avant Diagnostics' mailing address is 1050 30TH STREET NW SUITE 107, WASHINGTON DC, 20007. The company can be reached via email at [email protected].

This page was last updated on 11/28/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.